Evaluation of Anxiety Levels in Patients Undergoing Intravitreal Injections and Associated Risk Factors Related to the Disease

Table 2

Univariate linear regression analysis relating the levels of anxiety with the continuous and categorical variables.

Variable	Coefficient	value
Age (decades)	−3.19	0.116
Sex (female)	+10.79	0.031
Treatment experienced	−13.15	0.152
Number of previous injections	−0.02	0.922
Subjective number of previous injections	−0.09	0.617
Binocular BCVA	+13.96	0.139
Improvement in binocular BCVA	+30.3	0.093
Number of eyes treated (one)	+0.54	0.916
Change in treatment (no)	+4.30	0.392
Anti-VEGF
Bevacizumab	Reference
Ranibizumab	−7.11	0.228
Aflibercept	−14.59	0.046
Treated disease
AMD	Reference
DME	−0.36	0.947
RVO	−4.51	0.586
Others	+11.83	0.288

BCVA, best-corrected visual acuity; VEGF, vascular endothelial growth factor; AMD, age-related macular degeneration; DME, diabetic macular edema; RVO, retinal vein occlusion.